PCM
BLCM

Prelude Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Prelude Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40
Closed -$2K – 2263
2018
Q3 		$2K Buy
+40
New +$2.71K ﹤0.01% 1676

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's BLCM Position: Q4 2018 in Review

Prelude Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2018, closing a stake of 40 shares — an estimated $2K sold.

Prelude Capital Management first reported a position in BLCM in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 92 funds tracked by Wall St. Rank hold BLCM as of Q4 2018.

  • Prelude Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 40 Bellicum Pharmaceuticals, Inc. shares in Q4 2018, an estimated $2K.
  • Prelude Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Prelude Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $2K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.